Sri Lanka vs Upper-middle income (World Bank): HPV immunization coverage estimates among primary target cohort (9-14)
Sri Lanka
96.0%
in 2025
Upper-middle income (World Bank)
32.0%
in 2025
Sri Lanka rank
7th
Upper-middle income (World Bank) rank
6th
HPV immunization coverage estimates among primary target cohort (9-14) over time
- Sri Lanka
- Upper-middle income (World Bank)
How they compare
Sri Lanka currently reports 96.0% against 32.0% in Upper-middle income (World Bank), a difference of 64.0%.
That makes Sri Lanka's figure about 3.0 times Upper-middle income (World Bank)'s.
Across all 9 years both countries report, Sri Lanka has been ahead every year.
Sri Lanka ranks 7th and Upper-middle income (World Bank) ranks 6th of 111 countries.
Sri Lanka has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Sri Lanka | Upper-middle income (World Bank) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 83.7% | 21.0% | 62.7% | Sri Lanka |
| 2020s | 65.2% | 23.3% | 41.8% | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hpv immunization coverage estimates among primary target cohort (9-14), Sri Lanka or Upper-middle income (World Bank)?
- Sri Lanka, at 96.0% against 32.0% in Upper-middle income (World Bank) as of 2025.
- What is the difference in hpv immunization coverage estimates among primary target cohort (9-14) between Sri Lanka and Upper-middle income (World Bank)?
- 64.0%, with Sri Lanka ahead.
- How many years of comparable data are there for Sri Lanka and Upper-middle income (World Bank)?
- 9 years are reported by both, from 2017 to 2025.
- How do Sri Lanka and Upper-middle income (World Bank) rank globally for hpv immunization coverage estimates among primary target cohort (9-14)?
- Sri Lanka ranks 7th and Upper-middle income (World Bank) ranks 6th of 111 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HPV immunization coverage estimates among primary target cohort (9-14 years old girls) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.